HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Drug Pipeline
Guideline
Long-Acting ESAs for Renal Anemia in China: CERA Tops Assessment
New Assessment Scores Help Choose Treatments for Renal Anemia
CERA, pegmolesatide, and darbepoetin alfa all exceeded the 70-point threshold for strong recommendation in a Chinese health technology asses…
A new assessment identifies three long-acting drugs that meet high standards for safety and effectiveness in treating renal anemia.
Frontiers
Oct 12, 2026
Nephrology
Meta-analysis
HIF-prolyl hydroxylase inhibitors cause modest VEGF increases and reproducible peripheral edema in chronic kidney disease
New data shows how kidney disease drugs affect blood levels
This meta-analysis of 34 randomized controlled trials evaluated HIF-prolyl hydroxylase inhibitors in patients with chronic kidney disease. T…
A review of 34 trials shows that a specific type of kidney medication increases a protein called VEGF, but also carries a risk of swelling.
Oct 10, 2026
Nephrology
Meta-analysis
Roxadustat-based regimens result in higher mean hemoglobin levels than ESA-based regimens in peritoneal dialysis
Roxadustat shows higher hemoglobin levels for patients on peritoneal dialysis
This meta-analysis of 1636 adults with renal anemia indicates that roxadustat-based regimens lead to a mean difference of 7.30 g/L in post-t…
A new analysis shows roxadustat may raise hemoglobin levels and lower adverse event rates for adults on peritoneal dialysis.
Oct 7, 2026